• Molecular NameIbudilast (MN-166)
  • Synonym2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine; 3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine; AV-411; Eyevinal; I0157_SIGMA; Ibudilast (jan/inn); Ibudilast [inn:jan]; Ibudilastum; Ibudilastum [latin]; Ke tas; Ketas; Ketas (TN); Lopac-I-0157; MN-166; Pyrazolo(1,5-a)pyrdine, 3-isobutyryl-2-isopropyl-; Tocris-1694; UNII-M0TTH61XC5
  • Weight230.311
  • Drugbank_IDDB05266
  • ACS_NO50847-11-5
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.07
  • pkaN/A
  • LogD (pH=7, predicted)3.07
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.21
  • LogSw (predicted, AB/LogsW2.0)0.19
  • Sw (mg/ml) (predicted, ACD/Labs)0.14
  • No.of HBond Donors0
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds3
  • TPSA34.89
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyIbudilast (AV-411) is a non-selective phosphodiesterase inhibitor that is also known to suppress glial cell activation. It is tested for the treatment of asthma, neuropathic pain and opioid withdrawal syndromes.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A